tiprankstipranks
Abbvie (MX:ABBV)
NYSE:ABBV
Mexico Market
ABBV
AbbVie
RESEARCH TOOLSreports

AbbVie (ABBV) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

ABBV Analyst Ratings

Strong Buy
22Ratings
Strong Buy
18 Buy
4 Hold
0 Sell
Based on 22 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$4,751.57
Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $4,751.57 with a high forecast of $5,252.65 and a low forecast of $3,939.49. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3397":"$3,397","3861":"$3,861","4325":"$4,325","4789":"$4,789","5253":"$5,253"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5252.652591,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.25K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4751.566208906192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.75K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3939.48944325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.94K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3397,3861,4325,4789,5253],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4372.052,4439.790507,4507.529014,4575.267521,4643.006028,4710.744535,4778.483042,4846.221549,4913.960056,4981.698563,5049.43707,5117.175577,5184.914084,{"y":5252.652591,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4372.052,4401.245400685091,4430.438801370183,4459.632202055274,4488.825602740367,4518.019003425458,4547.21240411055,4576.405804795641,4605.599205480733,4634.7926061658245,4663.986006850917,4693.1794075360085,4722.3728082211,{"y":4751.566208906192,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4372.052,4338.777957173077,4305.503914346154,4272.22987151923,4238.9558286923075,4205.681785865385,4172.407743038461,4139.133700211538,4105.859657384615,4072.585614557692,4039.311571730769,4006.037528903846,3972.763486076923,{"y":3939.48944325,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3398.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3602.937,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3790.115,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4346.093,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3985.361,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4014.666,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4014.245,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3788.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3986.136,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3790.974,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3673.317,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3666.365,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4372.052,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$5,253Average Price Target$4,752Lowest Price Target$3,939
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:ABBV
Courtney Breen
Bernstein
Bernstein
$3,939.49
Hold
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Integer Holdings (NYSE: ITGR), Thermo Fisher (NYSE: TMO) and AbbVie (NYSE: ABBV)
Canaccord Genuity Analyst forecast on MX:ABBV
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$4,779.91→$4,937.49
Buy
―
Reiterated
07/22/26
AbbVie price target raised to $282 from $273 at CanaccordAbbVie price target raised to $282 from $273 at Canaccord
Goldman Sachs Analyst forecast on MX:ABBV
Asad Haider
Goldman Sachs
Goldman Sachs
$4,272.16
Hold
―
Reiterated
07/21/26
AbbVie: Neutral Stance Maintained as Fundamentals Improve and APGE-Driven Rally Leaves Valuation Fair; Price Target Reaffirmed at $244
Piper Sandler Analyst forecast on MX:ABBV
David Amsellem
Piper Sandler
Piper Sandler
$5,217.63
Buy
―
Reiterated
07/17/26
Analysts' Top Healthcare Picks: UnitedHealth (UNH), AbbVie (ABBV)
Citi Analyst forecast on MX:ABBV
Geoff Meacham
Citi
Citi
$4,027.03→$4,552.3
Hold
―
Reiterated
07/16/26
AbbVie price target raised to $260 from $230 at CitiAbbVie price target raised to $260 from $230 at Citi
William Blair Analyst forecast on MX:ABBV
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
07/15/26
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)
BMO Capital Analyst forecast on MX:ABBV
Evan Seigerman
BMO Capital
BMO Capital
$4,517.28→$5,252.65
Buy
―
Reiterated
07/13/26
AbbVie price target raised to $300 from $258 at BMO CapitalAbbVie price target raised to $300 from $258 at BMO Capital
UBS Analyst forecast on MX:ABBV
Michael Yee
UBS
UBS
$4,027.03→$4,552.3
Hold
―
Assigned
07/13/26
AbbVie price target raised to $260 from $230 at UBSAbbVie price target raised to $260 from $230 at UBS
Bank of America Securities Analyst forecast on MX:ABBV
Jason Gerberry
Bank of America Securities
Bank of America Securities
$4,097.07→$4,832.44
Buy
―
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Eli Lilly & Co (NYSE: LLY)
RBC Capital Analyst forecast on MX:ABBV
Trung Huynh
RBC Capital
RBC Capital
$4,552.3→$4,902.48
Buy
―
Assigned
07/10/26
Analysts Offer Insights on Healthcare Companies: TruBridge (NASDAQ: TBRG), AbbVie (NYSE: ABBV) and Nurix Therapeutics (NASDAQ: NRIX)
Wells Fargo Analyst forecast on MX:ABBV
Mohit Bansal
Wells Fargo
Wells Fargo
$4,552.3→$5,165.11
Buy
―
Assigned
07/10/26
Wells Fargo Sticks to Their Buy Rating for AbbVie (ABBV)
J.P. Morgan Analyst forecast on MX:ABBV
Chris Schott
J.P. Morgan
J.P. Morgan
$4,552.3→$4,902.48
Buy
―
Assigned
07/09/26
Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Corcept Therapeutics (CORT)
Guggenheim Analyst forecast on MX:ABBV
Vamil Divan
Guggenheim
Guggenheim
$4,359.7→$4,569.81
Buy
―
Reiterated
07/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Acadia Healthcare (NASDAQ: ACHC) and Medtronic (NYSE: MDT)
Scotiabank Analyst forecast on MX:ABBV
Louise Chen
Scotiabank
Scotiabank
$4,902.48
Buy
―
Reiterated
07/07/26
Scotiabank Sticks to Its Buy Rating for AbbVie (ABBV)
HSBC Analyst forecast on MX:ABBV
Rajesh Kumar
HSBC
HSBC
$4,814.93→$5,252.65
Buy
―
Reiterated
07/06/26
AbbVie price target raised to $300 from $275 at HSBCAbbVie price target raised to $300 from $275 at HSBC
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:ABBV
Courtney Breen
Bernstein
Bernstein
$3,939.49
Hold
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Integer Holdings (NYSE: ITGR), Thermo Fisher (NYSE: TMO) and AbbVie (NYSE: ABBV)
Canaccord Genuity Analyst forecast on MX:ABBV
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$4,779.91→$4,937.49
Buy
―
Reiterated
07/22/26
AbbVie price target raised to $282 from $273 at CanaccordAbbVie price target raised to $282 from $273 at Canaccord
Goldman Sachs Analyst forecast on MX:ABBV
Asad Haider
Goldman Sachs
Goldman Sachs
$4,272.16
Hold
―
Reiterated
07/21/26
AbbVie: Neutral Stance Maintained as Fundamentals Improve and APGE-Driven Rally Leaves Valuation Fair; Price Target Reaffirmed at $244
Piper Sandler Analyst forecast on MX:ABBV
David Amsellem
Piper Sandler
Piper Sandler
$5,217.63
Buy
―
Reiterated
07/17/26
Analysts' Top Healthcare Picks: UnitedHealth (UNH), AbbVie (ABBV)
Citi Analyst forecast on MX:ABBV
Geoff Meacham
Citi
Citi
$4,027.03→$4,552.3
Hold
―
Reiterated
07/16/26
AbbVie price target raised to $260 from $230 at CitiAbbVie price target raised to $260 from $230 at Citi
William Blair Analyst forecast on MX:ABBV
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
07/15/26
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)
BMO Capital Analyst forecast on MX:ABBV
Evan Seigerman
BMO Capital
BMO Capital
$4,517.28→$5,252.65
Buy
―
Reiterated
07/13/26
AbbVie price target raised to $300 from $258 at BMO CapitalAbbVie price target raised to $300 from $258 at BMO Capital
UBS Analyst forecast on MX:ABBV
Michael Yee
UBS
UBS
$4,027.03→$4,552.3
Hold
―
Assigned
07/13/26
AbbVie price target raised to $260 from $230 at UBSAbbVie price target raised to $260 from $230 at UBS
Bank of America Securities Analyst forecast on MX:ABBV
Jason Gerberry
Bank of America Securities
Bank of America Securities
$4,097.07→$4,832.44
Buy
―
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Eli Lilly & Co (NYSE: LLY)
RBC Capital Analyst forecast on MX:ABBV
Trung Huynh
RBC Capital
RBC Capital
$4,552.3→$4,902.48
Buy
―
Assigned
07/10/26
Analysts Offer Insights on Healthcare Companies: TruBridge (NASDAQ: TBRG), AbbVie (NYSE: ABBV) and Nurix Therapeutics (NASDAQ: NRIX)
Wells Fargo Analyst forecast on MX:ABBV
Mohit Bansal
Wells Fargo
Wells Fargo
$4,552.3→$5,165.11
Buy
―
Assigned
07/10/26
Wells Fargo Sticks to Their Buy Rating for AbbVie (ABBV)
J.P. Morgan Analyst forecast on MX:ABBV
Chris Schott
J.P. Morgan
J.P. Morgan
$4,552.3→$4,902.48
Buy
―
Assigned
07/09/26
Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Corcept Therapeutics (CORT)
Guggenheim Analyst forecast on MX:ABBV
Vamil Divan
Guggenheim
Guggenheim
$4,359.7→$4,569.81
Buy
―
Reiterated
07/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Acadia Healthcare (NASDAQ: ACHC) and Medtronic (NYSE: MDT)
Scotiabank Analyst forecast on MX:ABBV
Louise Chen
Scotiabank
Scotiabank
$4,902.48
Buy
―
Reiterated
07/07/26
Scotiabank Sticks to Its Buy Rating for AbbVie (ABBV)
HSBC Analyst forecast on MX:ABBV
Rajesh Kumar
HSBC
HSBC
$4,814.93→$5,252.65
Buy
―
Reiterated
07/06/26
AbbVie price target raised to $300 from $275 at HSBCAbbVie price target raised to $300 from $275 at HSBC
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
KURAKura Oncology
GKOSGlaukos
AHCOAdaptHealth
VTVTvTv Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months
Carter GouldCantor Fitzgerald
Success Rate
13/17 ratings generated profit
76%
Average Return
+8.99%
Copying Carter Gould's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +8.99% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
24/24 ratings generated profit
100%
Average Return
+22.27%
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.27% per trade.
2 Years
Carter GouldCantor Fitzgerald
Success Rate
17/17 ratings generated profit
100%
Average Return
+38.74%
Copying Carter Gould's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +38.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
30
45
45
53
41
Hold
14
11
8
11
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
56
53
64
51
In the current month, ABBV has received 41 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 4,751.57.
Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $63.12 with a range of $62.51 to $64.96. The previous quarter’s EPS was $46.40. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABBV is $63.12 with a range of $62.51 to $64.96. The previous quarter’s EPS was $46.40. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $293.92B with a range of $291.48B to $297.24B. The previous quarter’s sales results were $262.67B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.
Next quarter’s sales forecast for ABBV is $293.92B with a range of $291.48B to $297.24B. The previous quarter’s sales results were $262.67B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Stock Forecast FAQ

What is MX:ABBV’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbvie’s 12-month average price target is 4,751.57.
    What is MX:ABBV’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:ABBV, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Abbvie a Buy, Sell or Hold?
        Abbvie has a consensus rating of Strong Buy, which is based on 18 buy ratings, 4 hold ratings and 0 sell ratings.
          What is Abbvie’s share price target?
          The average share price target for Abbvie is 4,751.57. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $5,252.65 ,and the lowest forecast is $3,939.49. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Abbvie?
            Abbvie’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
              How can I buy shares of Abbvie?
              To buy shares of MX:ABBV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.